H
Hammad Ali
Researcher at University of New South Wales
Publications - 62
Citations - 5111
Hammad Ali is an academic researcher from University of New South Wales. The author has contributed to research in topics: Population & Vaccination. The author has an hindex of 24, co-authored 60 publications receiving 4468 citations. Previous affiliations of Hammad Ali include Centers for Disease Control and Prevention & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies
Louisa Degenhardt,Chiara Bucello,Bradley Mathers,Christina Briegleb,Hammad Ali,Matthew Hickman,Jennifer McLaren +6 more
TL;DR: Mortality among opioid-dependent users varies across countries and populations; treatment is clearly protective against mortality even in non-randomized observational studies; study characteristics predict mortality levels.
Journal ArticleDOI
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.
Bradley Mathers,Louisa Degenhardt,Hammad Ali,Lucas Wiessing,Matthew Hickman,Richard P. Mattick,Bronwyn Myers,Atul Ambekar,Steffanie A. Strathdee +8 more
TL;DR: Worldwide coverage of HIV prevention, treatment, and care services in IDU populations is very low, and there is an urgent need to improve coverage of these services in this at-risk population.
Journal ArticleDOI
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes : updated systematic review and meta-analysis
Mélanie Drolet,Élodie Bénard,Norma Pérez,Marc Brisson,Marc Brisson,Hammad Ali,Marie-Claude Boily,Vincenzo Baldo,Paul Brassard,Julia M.L. Brotherton,Denton Callander,Marta Checchi,Eric P F Chow,Silvia Cocchio,Tina Dalianis,Shelley L Deeks,Christian Dehlendorff,Basil Donovan,Christopher K Fairley,Elaine W. Flagg,Julia W Gargano,Suzanne M. Garland,Nathalie Grün,Bo T. Hansen,Christopher Harrison,Eva Herweijer,Teresa M. Imburgia,Anne M Johnson,Jessica A. Kahn,Kimberley Kavanagh,Susanne K. Kjaer,Erich V. Kliewer,Bette Liu,Dorothy A Machalek,Lauri E. Markowitz,David Mesher,Christian Munk,Linda M. Niccolai,Mari Nygård,Gina Ogilvie,Jeannie Oliphant,Kevin G.J. Pollock,Maria Jesús Purriños-Hermida,Megan Smith,Marc Steben,Anna Söderlund-Strand,Pam Sonnenberg,Pär Sparén,Clare Tanton,Cosette M. Wheeler,Petra J Woestenberg,Bo Nancy Yu +51 more
TL;DR: The results show compelling evidence of the substantial impact of HPV vaccination programmes on HPV infections and CIN2+ among girls and women, and on anogenital warts diagnoses among girls, women, boys, and men.
Journal ArticleDOI
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
Mélanie Drolet,Élodie Bénard,Marie-Claude Boily,Marie-Claude Boily,Hammad Ali,Louise Baandrup,Heidi M. Bauer,Simon Beddows,Jacques Brisson,Julia M.L. Brotherton,Teresa Cummings,Basil Donovan,Christopher K Fairley,Elaine W. Flagg,Anne M Johnson,Jessica A. Kahn,Kimberley Kavanagh,Susanne K. Kjaer,Erich V. Kliewer,Philippe Lemieux-Mellouki,Lauri E. Markowitz,Aminata Mboup,David Mesher,Linda M. Niccolai,Jeannie Oliphant,Kevin G.J. Pollock,Kate Soldan,Pam Sonnenberg,Sepehr N. Tabrizi,Sepehr N. Tabrizi,Clare Tanton,Marc Brisson,Marc Brisson +32 more
TL;DR: The results are promising for the long-term population-level effects of HPV vaccination programmes, however, continued monitoring is essential to identify any signals of potential waning efficacy or type-replacement.
Journal ArticleDOI
Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data
Hammad Ali,Basil Donovan,Basil Donovan,Handan Wand,Tim R H Read,David G. Regan,Andrew E. Grulich,Christopher K Fairley,Rebecca Guy +8 more
TL;DR: The significant declines in the proportion of young women found to have genital wart and the absence of genital warts in vaccinated women in 2011 suggests that the human papillomavirus vaccine has a high efficacy outside of the trial setting.